ClinicalTrials.Veeva

Menu

Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration

Sanofi logo

Sanofi

Status and phase

Active, not recruiting
Phase 2

Conditions

Stargardt's Disease

Treatments

Drug: Long term follow up in all patients who received SAR422459 in previous study TDU13583

Study type

Interventional

Funder types

Industry

Identifiers

NCT01736592
LTS13588
2024-513501-31 (Registry Identifier)
SG1/002/11
2012-001990-95 (EudraCT Number)

Details and patient eligibility

About

Primary Objective:

To evaluate the long-term safety and tolerability of SAR422459 in patients with Stargardt's Macular Degeneration.

Secondary Objective:

To assess:

  • Safety
  • Biological activity

Full description

Patients will be followed for 15 years after completion/early termination from the previous TDU13583 study (NCT01367444).

As the initial TDU13583 study is terminated - recruitment to this LTS13588 study is over with 27 patients enrolled.

Enrollment

27 patients

Sex

All

Ages

6+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients must meet ALL of the following criteria:

  1. Provide signed and dated written informed consent and any locally required authorization (e.g., Health Insurance Portability and Accountability Act [HIPAA])
  2. Must have been enrolled in protocol TDU13583 (SG1/001/10)
  3. Must have received a subretinal injection of SAR422459
  4. Must have completed protocol TDU13583 to Week 48 or undergone an early discontinuation visit.

Exclusion criteria

The following would exclude Patients from participation in the study:

  1. Did not receive SAR422459 as part of the TDU13583 protocol.

Trial design

Primary purpose

Other

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

27 participants in 1 patient group

Long Term Follow up
Other group
Description:
Long term follow up in all patients who received SAR422459 in previous study TDU13583
Treatment:
Drug: Long term follow up in all patients who received SAR422459 in previous study TDU13583

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems